> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Omnicare Pays $28 Million to Resolve Abbott Kickback Probe
- URL: https://www.fdaweb.com/omnicare-pays-28-million-to-resolve-abbott-kickback-probe/
- Published: 2016-10-17T12:00:00.000Z
- Updated: 2026-09-14T21:39:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137094

Omnicare has agreed to pay $28 million to resolve allegations that it solicited and received kickbacks from Abbott Laboratories in exchange for promoting the anti-epileptic drug Depakote for nursing home patients. In 2012, the government and [Abbott](https://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote?ref=fdaweb.com) entered into a $1.5 billion global civil and criminal resolution that resolved Abbott’s liability under the False Claims Act for Omnicare and other nursing home alleged kickbacks, according to a U.S. Department of Justice [release](https://www.justice.gov/opa/pr/nation-s-largest-nursing-home-pharmacy-pay-over-28-million-settle-kickback-allegations?ref=fdaweb.com).

According to the government’s complaint, Omnicare disguised the kickbacks it received from Abbott as “grants” and “educational funding,” even though their true purpose was to induce Omnicare to recommend Depakote. It also alleged that Omnicare entered into agreements with Abbott by which Omnicare was entitled to increasing levels of rebates from Abbott based on the number of nursing home residents serviced and the amount of Depakote prescribed per resident.